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Abstract
Cost-effectiveness data is useful for use in priority setting decisions in order to improve the efficiency of resources 
used. This paper thereby responds to Eckard et al. which addressed the use of cost-effectiveness data in the actual 
prioritization decisions in the Swedish national clinical guidelines for heart diseases. Based on a set of experiences 
on the use of economic evaluation in priority setting processes, this paper emphasizes the potential approach to 
incorporating cost-effectiveness data in the prioritization process to enhance transparency of the decisions, and 
highlights the importance of designing a fair decision-making process that can enforce the sustained implementation 
of cost-effectiveness data.
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The World Health Report 2010 estimated that around 40% of total healthcare expenditures in all healthcare settings have been wasted (1). Health economic 
evaluation and its components such as cost-effectiveness 
analysis, has been employed as an explicit consideration 
for guiding efficient resource use. However, the practical 
implementations of incorporating cost-effectiveness data in 
priority decisions of a wide array of health policy issues (2) 
are inadequate. This paper thereby responds to an article by 
Eckard et al. (3), in which the authors address the use of cost-
effectiveness data in Swedish priority setting for producing 
evidence-based national clinical guidelines for heart diseases. 
The article also reveals a number of obstacles that limit the use 
of cost-effectiveness data in actual decision-making including 
lack of trust in the available data, limited understanding of the 
data and the difficult balancing between cost-effectiveness 
data and other types of evidence. In recognizing the need for 
improving efficiency of the use of cost-effectiveness data in 
priority setting processes, this paper proposes three potential 
approaches to overcome these obstacles. 
First, focusing on distrust in cost-effectiveness data, 
methodological and contextual issues would affect decision-
makers’ acceptance of the data. Empirical research has shown 
that one of the reasons for rejecting or partially accepting 
the use of evidence, generated in other settings, is that the 
decision-makers are aware of diversities in social, economic, 
and health backgrounds across settings. This rationale is 
supported by the suggestion from a study by Teerawattananon 
et al. (4) where the decision-making processes for including 
health interventions in the Thai universal health coverage 
benefit package was examined. The Thai study highlights 
that cost-effectiveness data generated in the local context 
will be more acceptable and reasonable for the decision-
makers, and it is plausible that this also applies in making 
recommendations in the clinical guidelines.
Second approach regards to the issue of decision-makers’ 
limited understanding of cost-effectiveness data. Several 
scholars (4,5) including Eckard et al. (3) indicated that 
even if cost-effectiveness data were available, the decision-
makers may not be willing to use the data as a tool in their 
decisions due to a lack of understanding. Decision-makers 
are not usually familiar with cost-effectiveness data and its 
interpretation in clinical issues. The concept of the common 
outcomes of cost-effectiveness analysis – quality-adjusted 
life years – is not intuitively understood by most clinicians 
or policy-makers, and its current use may not be seen as 
reasonably measured in the clinician’s perspective (6,7). 
Improving the decision-makers’ understanding of cost-
effectiveness data is needed; otherwise, the use of the data 
in decision-making is unlikely to happen. The inclusion 
of health economists in the prioritization process is indeed 
important – as in the case of the Swedish framework (3) – to 
help explaining interpretation and improving understanding 
of scientific content for decision-makers who are non-health 
economists.
Third, to address the issue of the difficulty of balancing cost-
effectiveness data with other evidence, the development of a 
multi-criteria approach to priority setting has recently been 
identified as one of the most important issues in prioritizing 
decision-making processes (8,9), including in guidelines 
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development (10). In short, cost-effectiveness data, clinical 
evidence, and the evidence of other important factors should 
be used in combination as part of holistic decision-making 
processes. Besides the incorporation of cost-effectiveness 
data in decision-making, social values come into play (11–
13). Some Thai studies revealed that the incorporation of 
social values of equity into decision-making can enhance 
the acceptance of cost-effectiveness data (4,13,14). Health 
interventions that are not cost-effectiveness may still be 
recommended in the clinical guidelines if there are other 
strong supporting factors. 
The above-mentioned section illustrates a number of 
approaches that could improve the use of cost-effectiveness 
data in prioritizing decision-making and thereby enhance 
transparency of the priority setting decisions. Based on 
Thailand’s experience, cost-effectiveness data is a very 
useful guiding tool to inform national policy decision-
making in important health issues, including development 
of the universal coverage health benefit package (14) 
and development of the national list of pharmaceutical 
reimbursement (15). This accomplishment of incorporating 
cost-effectiveness data as well as other relevant evidence in 
the national health priority setting decision-making process 
is a long journey that requires a number of supporting factors, 
including commitment from all stakeholders involved in 
the process and the willingness to use the evidence of the 
decision-makers at every level. 
Moreover, priority setting decisions in general are largely 
made in the context of scientific uncertainty and priority 
setting itself is a dynamic process. There is no gold standard 
to judge the adequacy of priority setting decisions. Therefore, 
the only attempt of incorporating scientific evidence, such 
as cost-effectiveness data, in priority setting process may 
not help improving the rational decision-making. Instead 
the ‘Accountability for Reasonableness’ (A4R) framework 
(16) proposes to concentrate more on a ‘fair’ priority setting 
process that specifies conditions for fair decision-making: 
reasonableness, publicity, revisable, and enforcement (9). 
In doing so, the framework considers aspects of rational 
and transparency at the same time. Therefore, this paper 
proposes a number of recommendations for priority setting 
process, on the basis of the Thai experience on development 
of the universal coverage health benefit package (17), that 
incorporate cost-effectiveness evidence and include the 
fair notions. 
First, strengthening explicit and rational priority setting in 
healthcare requires the involvement of all relevant multiple 
stakeholders right from the beginning of the priority setting 
process. This is to include all relevant perspectives to improve 
legitimacy of final decisions. Again, to make effective use of 
cost-effectiveness data, health economists should be one of 
the stakeholders involved in the process.
Second, it is important to have a locally meaningful set of 
priority setting criteria by consulting the panel, and to design 
the way to assess the performance of a set of interventions 
on the criteria. This is to present the reasonableness and 
transparency of the process.
Third, the reliability of prioritizing decision-making cannot 
be guaranteed if there is no comparable local evidence for 
supporting the assessment of the interventions’ performance. 
Therefore, country-specific and more reliable evidence should 
be developed in a uniform methodology.
Fourth, setting healthcare priorities is not likely to succeed 
without considering deliberative processes among the 
concerned stakeholders. Although all evidence are collected 
and used in the process, decision-makers still require room 
to justify their own reasons in the final step to maintain their 
authority in decision-making (9). Some considerations such 
as social and ethical considerations cannot be measured as 
objective parameters, and are usually applied in the decision-
making as subjective descriptions. Although the deliberative 
process for making recommendations in the clinical practice 
guidelines involve mainly clinical expert groups, such as 
medical specialists, clinical professionals, and a health 
economist as in the case of the Swedish framework, there 
are some scholars who support the idea of patient and public 
involvement in the clinical practice guidelines development 
to make the recommendations more acceptable and adherent 
to the treatment choice (18,19). 
In summary, Eckard et al. (3) have highlighted the use 
of cost-effectiveness data in real-world decision-making 
processes and this paper emphasizes the potential approach 
to incorporating cost-effectiveness data in priority setting 
processes to enhance reasonableness and transparency 
of the decisions and the importance of designing a fair 
decision-making process that can support the continuous 
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